source
- FDA approves trastuzumab deruxtecan for early-stage HER2-positive breast cancerThe U.S. Food and Drug Administration has granted approval for trastuzumab deruxtecan (T‑DXd) as a treatment option in both the adjuvant and neoadjuvant settings for certain patients with early-sta…
- FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancer, says Dr. HafronThe U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with MRD-positive muscle-invasive bladder cancer. The decision expands the use of the immunotherapy…